Market Data
Market Cap₹127.23 Cr.
52W High₹76.72
Current Price₹59.01
52W Low₹38.52
Down from 52W High23.1 %
Face Value₹10
Performance
ROCE-10.92 %
ROE8.66 %
EPS (TTM)₹-1.15
EPS Prev Qtr₹-1.09
EPS Last Year₹-2.85
EBITDA Qtr₹-0.76 Cr.
Book Value₹-76
Financial Health
Debt/Equity-1.38
Debt/Profit-15.96
Total Assets₹163.25 Cr.
Promoter Holding72.74 %
Earning Power-5.48 %
Valuation
Industry P/E33.3
Price to Book-0.78
Price to Sales5.04
Key Metrics
Face Value
₹10
About Krebs Biochemicals & Industries Ltd
Healthcare · Pharmaceuticals
Krebs Biochemicals & Industries Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹127.23 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- Promoter holding stands at 72.74%, indicating strong management control and alignment of interests.
- ROE is positive at 9.63%, suggesting some level of return generation for shareholders despite current losses.
Weaknesses
- The company is reporting a net loss of ₹14.09 Cr, indicating poor profitability.
- P/E ratio is negative at -8.57, reflecting ongoing losses and lack of earnings.
- P/B ratio is negative at -0.83, signaling negative book value which may raise concerns about asset valuation.
- ROCE is negative at -10.28%, indicating inefficient use of capital and poor returns on invested capital.
- Debt to Equity ratio is negative at -1.45, suggesting unusual accounting treatment or potential liabilities exceeding equity.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 4.17 | 7.27 | 6.81 | 6.98 |
| ↳ QoQ Growth | - | +74.3% | -6.3% | +2.5% |
| Expenses | 8.58 | 8.61 | 9.24 | 7.74 |
| Operating Profit | -4.42 | -1.34 | -2.43 | -0.76 |
| OPM % | -106% | -18.43% | -35.68% | -10.89% |
| Other Income | 0.01 | 0 | 2 | 0.16 |
| Interest | 1.73 | 1.79 | 1.91 | 1.88 |
| Depreciation | 1.62 | 1.63 | 1.57 | 1.59 |
| EBITDA | -2.8 | 0.29 | -0.86 | 0.83 |
| EBITDA Margin % | -67.15% | 3.99% | -12.63% | 11.89% |
| Profit Before Tax | -6.14 | -3.13 | -2.34 | -2.48 |
| Tax % | 0% | 0% | 0% | 0% |
| Net Profit | -6.14 | -3.13 | -2.34 | -2.48 |
| ↳ QoQ Growth | - | +49.0% | +25.2% | -6.0% |
| EPS | -2.85 | -1.45 | -1.09 | -1.15 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 21.5606 | 21.56 |
| Reserves | -167.7994 | -184.32 |
| Borrowings | 212.21 | 224.84 |
| Other Liabilities | 103.06 | 101.17 |
| Total Liabilities | 169.0356 | 163.25 |
| Fixed Assets | 147.5518 | 141.42 |
| CWIP | 1.2403 | 1.59 |
| Investments | 0 | 0 |
| Other Assets | 20.24 | 20.24 |
| Total Assets | 169.0356 | 163.25 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | -7.891 | -1.9205 |
| Cash from Investing Activity | -4.9696 | -3.6358 |
| Cash from Financing Activity | 12.8648 | 5.5438 |
| Net Cash Flow | 0.0042 | -0.0125 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 72.74% | 72.74% | 72.74% | 72.74% |
| FIIs % | 0.5% | 0.49% | 0.5% | 0.5% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 19.7% | 19.8% | 19.81% | 19.67% |
| No. of Shareholders | 8,912 | 8,710 | 8,553 | 8,521 |
Major Shareholders (>1%)
- Ipca Laboratories LimitedPromoter and Promoter Group49.65%
- Hemalatha RaviPromoter and Promoter Group12.48%
- Avinash RaviPromoter and Promoter Group9.93%
- Sun Pharmaceutical Industries LtdPublic Shareholding4.81%
As of 2026-06-30View all shareholders →